Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Agios announces the submission of its sNDA to the FDA for the U.S. accelerated approval of mitapivat in sickle cell disease
-
Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026
-
Agios announces first quarter 2026 financial results and provides business update.
-
Agios will report its first quarter 2026 financial results and business highlights on Wednesday, April 29, 2026.
-
Agios announces it will pursue U.S. accelerated approval for mitapivat in sickle cell disease
-
PYRUKYND (mitapivat) approved for adults with thalassemia in the United Arab Emirates
-
Agios (Nasdaq: AGIO) announces financial results and updates for the fourth quarter and year ended December 31, 2025.
-
Agios announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its 4Q and full year
-
Agios today announced its 2026 strategic priorities and key milestones anticipated during the year.
-
Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026